Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi To Expand India Market To Rural Areas

This article was originally published in PharmAsia News

Executive Summary

French drug maker Sanofi-Aventis plans to expand its year-old development center in India to market non-specialty domestic drugs to rural areas. The firm plans to emphasize cough and cold medicines and treatments for infections and minor ailments. The managing director of Aventis Pharma, Sanofi's India branch, said the company seeks to acquire "suitable brands and businesses here." Sanofi has been a key supplier of products for the Indian diabetes market. (Click here for more

You may also be interested in...



Spanish Consumer Health And Cosmetics Firms Eying Up China’s Online Self-Care Market

A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall. 

NeuClone Makes Progress On Ustekinumab

Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.

Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES

Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel